Back to top
more

Accelerate Diagnostics (AXDX)

(Delayed Data from NSDQ)

$1.93 USD

1.93
72,441

+0.01 (0.52%)

Updated Nov 1, 2024 03:59 PM ET

After-Market: $1.93 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Inari Medical, Inc. (NARI) Reports Q3 Loss, Tops Revenue Estimates

Inari Medical (NARI) delivered earnings and revenue surprises of -8.33% and 1.72%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Accelerate Diagnostics Stock Down Despite FDA Clearance for Arc System

AXDX's Arc system gains FDA clearance, automating blood culture prep for faster microbial ID, improved sepsis outcomes and reduced hospital costs.

Accelerate Diagnostics (AXDX) Completes WAVE Pre-Clinical Trial

Accelerate Diagnostics (AXDX) is confident about WAVE product design and the system's capabilities after the successful completion of the pre-clinical trial.

Accelerate Diagnostics (AXDX) Reports Q2 Loss, Misses Revenue Estimates

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 9.09% and 0.47%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Silk Road Medical (SILK) Reports Q2 Loss, Tops Revenue Estimates

Silk Road Medical (SILK) delivered earnings and revenue surprises of -10.53% and 3.30%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

InspireMD, Inc. (NSPR) Reports Q2 Loss, Misses Revenue Estimates

InspireMD (NSPR) delivered earnings and revenue surprises of -15.79% and 0.06%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Delcath Systems, Inc. (DCTH) Reports Q2 Loss, Tops Revenue Estimates

Delcath Systems (DCTH) delivered earnings and revenue surprises of -41.18% and 55.32%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Ekso Bionics (EKSO) Reports Q2 Loss, Lags Revenue Estimates

Ekso Bionics (EKSO) delivered earnings and revenue surprises of -18.18% and 7.30%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Accelerate Diagnostics (AXDX) Reports Q1 Loss, Misses Revenue Estimates

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of -22.22% and 2.63%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Treace Medical Concepts (TMCI) Reports Q1 Loss, Tops Revenue Estimates

Treace Medical Concepts (TMCI) delivered earnings and revenue surprises of 0% and 4.22%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Will Accelerate Diagnostics (AXDX) Report Negative Q1 Earnings? What You Should Know

Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Accuray (ARAY) Reports Q3 Loss, Lags Revenue Estimates

Accuray (ARAY) delivered earnings and revenue surprises of -500% and 11.75%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Accelerate Diagnostics (AXDX) Reports Q4 Loss, Misses Revenue Estimates

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of -43.55% and 20.34%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Accelerate Diagnostics (AXDX) Expands in In Vitro Diagnostics

Accelerate Diagnostics' (AXDX) Arc system eliminates the need for overnight culture incubation, drastically reducing the wait time for identification results.

Bruker's (BRKR) New Collaboration to Use MALDI Biotyper System

Bruker (BRKR) and Accelerate Diagnostics are set to work together to bring rapid, automated microbial identification directly from positive blood culture samples.

Accelerate Diagnostics (AXDX) Loses -25.65% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Accelerate Diagnostics (AXDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Accelerate Diagnostics (AXDX) Moves 12.7% Higher: Will This Strength Last?

Accelerate Diagnostics (AXDX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Accelerate Diagnostics (AXDX) Reports Q2 Loss, Misses Revenue Estimates

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of -57.33% and 26.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

OPKO Health (OPK) Reports Q2 Loss, Tops Revenue Estimates

OPKO Health (OPK) delivered earnings and revenue surprises of 57.14% and 39.44%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Is Accelerate Diagnostics (AXDX) Stock Outpacing Its Medical Peers This Year?

Here is how Accelerate Diagnostics (AXDX) and BellRing Brands (BRBR) have performed compared to their sector so far this year.

Is Akero Therapeutics (AKRO) Outperforming Other Medical Stocks This Year?

Here is how Akero Therapeutics, Inc. (AKRO) and Accelerate Diagnostics (AXDX) have performed compared to their sector so far this year.

Is Accelerate Diagnostics (AXDX) Outperforming Other Medical Stocks This Year?

Here is how Accelerate Diagnostics (AXDX) and Cognition Therapeutics, Inc. (CGTX) have performed compared to their sector so far this year.

Accelerate Diagnostics (AXDX) Reports Q1 Loss, Misses Revenue Estimates

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 0% and 19.66%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Syneos Health (SYNH) Announces a $7.1 Billion Merger Agreement

Syneos Health (SYNH) is set to become private company following a $7.1 billion merger deal to be acquired by a private investment consortium.

Walgreens Boots (WBA) New Alliances Aid Growth, Cost Woe Stays

Intensifying competition in the U.S. pharmacy retail drugstore market compels Walgreens Boots (WBA) to diversify its product offerings through new partnerships.